Sanofi ( $SNY ) may want to thank its lucky stars that its new Genzyme plant won FDA approval when it did. The facility in Framingham, MA, will allow the French drugmaker's rare-disease unit to get back on track with its Fabry disease drug Fabrazyme . It may also have deterred Shire from pursuing its own Fabry drug application in the face of complications at the FDA.
Sanofi ( $SNY ), which has spent the last year trimming manufacturing and R&D operations around the globe, has taken aim at another U.K. facility.
Litigation is testing whether manufacturing problems at a pharmaceutical plant that led to a drug shortage can be considered legal negligence--as well as whether the manufacturer can be held accountable for patients' deaths.
Eli Lilly ( $LLY ) says it will invest €330 million in its previously announced expansion at its Kinsale campus in Ireland. Work is beginning at the 240,000-square-foot commercialization and...
As part of an ongoing restructuring effort, Sanofi ( $SNY ) is shuttering Genzyme 's Cambridge, U.K., R&D operation by the end of the year.
With European approval, Shire ( $SHPGY ) is ready to start production at its new $200 million, energy efficient plant in Lexington, MA. The EMA has given the biopharmaceutical company the green light...
Shire 's rare-disease challenge is heating up.
Here's another ripple from the Ben Venue Laboratories splashdown. Sanofi's ( $SNY ) Genzyme unit has recalled a batch of its leukemia drug Fludara because of worries about its sterility. The 9,380
This is the year that the patent cliff arrives with a vengeance at Sanofi ( $SNY ). With copycat versions of Plavix and Avapro gobbling market share, the pharma giant predicted a 15% plunge in profits
It wasn't Sanofi's fourth-quarter profits, which grew by 13%. Nor was it the 8.8% increase in sales for the period, or the 5.3% increase in 2011 sales, to €33.39 billion ($44.3...